Patient Feedback Proves Vital for Multiple Sclerosis Drug Trials
As originally reported in EurekAlert, creating effective rare disease pharmaceuticals is difficult. Yes, because it is expensive, there’s a small population to use in trials, and there’s limited research. Sometimes…